50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Poverty, inflation, fear: Egypt's economy pushed to brink
One Stock Doubles Your Money, During Crisis? (Ad)
Labour conference starts with focus on 'immoral' tax cuts
German leader continues Gulf tour with stops in UAE, Qatar
One Stock Doubles Your Money, During Crisis? (Ad)
Germany secures more gas shipments as Scholz visits Gulf
Poverty and inflation: Egypt's economy hit by global turmoil
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Poverty, inflation, fear: Egypt's economy pushed to brink
One Stock Doubles Your Money, During Crisis? (Ad)
Labour conference starts with focus on 'immoral' tax cuts
German leader continues Gulf tour with stops in UAE, Qatar
One Stock Doubles Your Money, During Crisis? (Ad)
Germany secures more gas shipments as Scholz visits Gulf
Poverty and inflation: Egypt's economy hit by global turmoil
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Poverty, inflation, fear: Egypt's economy pushed to brink
One Stock Doubles Your Money, During Crisis? (Ad)
Labour conference starts with focus on 'immoral' tax cuts
German leader continues Gulf tour with stops in UAE, Qatar
One Stock Doubles Your Money, During Crisis? (Ad)
Germany secures more gas shipments as Scholz visits Gulf
Poverty and inflation: Egypt's economy hit by global turmoil
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Poverty, inflation, fear: Egypt's economy pushed to brink
One Stock Doubles Your Money, During Crisis? (Ad)
Labour conference starts with focus on 'immoral' tax cuts
German leader continues Gulf tour with stops in UAE, Qatar
One Stock Doubles Your Money, During Crisis? (Ad)
Germany secures more gas shipments as Scholz visits Gulf
Poverty and inflation: Egypt's economy hit by global turmoil
NASDAQ:VVOS

Vivos Therapeutics - VVOS Stock Forecast, Price & News

$0.83
-0.08 (-8.81%)
(As of 09/23/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.72
$0.91
50-Day Range
$0.83
$1.42
52-Week Range
$0.72
$4.72
Volume
117,619 shs
Average Volume
24,258 shs
Market Capitalization
$19.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Vivos Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
504.0% Upside
$5.00 Price Target
Short Interest
Bearish
1.00% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.00) to ($0.50) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.26 out of 5 stars

Medical Sector

1047th out of 1,075 stocks

VVOS stock logo

About Vivos Therapeutics (NASDAQ:VVOS) Stock

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.

Receive VVOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vivos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VVOS Stock News Headlines

See More Headlines
Receive VVOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vivos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VVOS Company Calendar

Last Earnings
11/15/2021
Today
9/25/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
N/A
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VVOS
Fax
N/A
Employees
147
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+504.0%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$16.89 million

Miscellaneous

Free Float
20,343,000
Market Cap
$19.05 million
Optionable
Not Optionable
Beta
0.88

Key Executives

  • Mr. R. Kirk Huntsman (Age 64)
    Co-Founder, Chairman & CEO
    Comp: $506.85k
  • Mr. Bradford K. AmmanMr. Bradford K. Amman (Age 60)
    CFO, Treasurer & Sec.
    Comp: $300.53k
  • Mr. Todd Huntsman
    Co-Founder & Sr. VP of Product and Technology
  • Ms. RaeAnn Byrnes
    Co-Founder and Sr. VP of Events & Clinical Advisory Services
  • Ms. Susan McCullough
    Co-Founder & Exec. VP
  • Ms. Julie Gannon
    Chief of Staff & Investor Relations
  • Mr. George A. Gardiner
    Sr. VP of Sales
  • Mr. Nicholas M. DeGennaro
    Sr. VP of the Medical Integration Division
  • Ms. Ruth Hembree
    Sr. VP of Practice Services
  • Ms. Stephanie Huebner
    Sr. VP of DSO Operations













VVOS Stock - Frequently Asked Questions

What is Vivos Therapeutics' stock price forecast for 2022?

0 brokers have issued 1 year price targets for Vivos Therapeutics' shares. Their VVOS share price forecasts range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 504.0% from the stock's current price.
View analysts price targets for VVOS
or view top-rated stocks among Wall Street analysts.

How have VVOS shares performed in 2022?

Vivos Therapeutics' stock was trading at $2.25 at the beginning of the year. Since then, VVOS shares have decreased by 63.2% and is now trading at $0.8278.
View the best growth stocks for 2022 here
.

When is Vivos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our VVOS earnings forecast
.

How were Vivos Therapeutics' earnings last quarter?

Vivos Therapeutics, Inc. (NASDAQ:VVOS) posted its quarterly earnings data on Monday, November, 15th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.10. The company earned $4.55 million during the quarter, compared to the consensus estimate of $4.50 million.

When did Vivos Therapeutics IPO?

(VVOS) raised $20 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 3,300,000 shares at $5.00-$7.00 per share. Roth Capital Partners acted as the underwriter for the IPO and Craig-Hallum Capital Group and National Securities Corporation were co-managers.

What is Vivos Therapeutics' stock symbol?

Vivos Therapeutics trades on the NASDAQ under the ticker symbol "VVOS."

Who are Vivos Therapeutics' major shareholders?

Vivos Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Russell Investments Group Ltd. (1.79%) and Perkins Capital Management Inc. (0.71%). Insiders that own company stock include Bradford K Amman and Ronald Kirk Huntsman.
View institutional ownership trends
.

How do I buy shares of Vivos Therapeutics?

Shares of VVOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vivos Therapeutics' stock price today?

One share of VVOS stock can currently be purchased for approximately $0.83.

How much money does Vivos Therapeutics make?

Vivos Therapeutics (NASDAQ:VVOS) has a market capitalization of $19.05 million and generates $16.89 million in revenue each year.

How many employees does Vivos Therapeutics have?

The company employs 147 workers across the globe.

How can I contact Vivos Therapeutics?

The official website for the company is www.vivoslife.com. The company can be reached via phone at 866 908 4867 or via email at jgannon@vivoslife.com.

This page (NASDAQ:VVOS) was last updated on 9/25/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.